Neurogene Inc. also files under NLTX, AQXP; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 4K | $36.13 | $152K |
| Jul 6, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 600 | $36.02 | $22K |
| Jul 2, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 3K | $34.58 | $88K |
| Jul 2, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 2K | $35.23 | $54K |
| Jul 1, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 739 | $34.06 | $25K |
| May 6, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 5K | $32.44 | $156K |
| May 6, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 5K | $30.07 | $144K |
| May 5, 2026 | Shafer Christina | Chief Commercial Officer | Grant(A) | 120K | — | $0 |
| Mar 26, 2026 | McMinn Rachel | Chief Executive Officer, Director | Sell(S) | 3K | $22.07 | $74K |
| Mar 26, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 3K | $21.62 | $55K |
| Mar 26, 2026 | Jordan Julie | Chief Medical Officer | Sell(S) | 828 | $21.89 | $18K |
| Mar 13, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 1K | $21.25 | $30K |
| Mar 13, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 263 | $22.02 | $6K |
| Mar 13, 2026 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 148 | $22.08 | $3K |
| Mar 13, 2026 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 4K | $20.41 | $81K |
| Mar 13, 2026 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 3K | $21.34 | $57K |
| Mar 13, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 2K | $20.42 | $49K |
| Feb 27, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 5K | $25.11 | $121K |
| Feb 20, 2026 | Jordan Julie | Chief Medical Officer | Grant(A) | 5K | — | $0 |
| Feb 20, 2026 | Freedland Cory S. | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Noonberg Sarah B. | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Cvijic Christine Mikail | President and CFO | Grant(A) | 22K | — | $0 |
| Feb 20, 2026 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 155K | — | $0 |
| Feb 20, 2026 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 26K | — | $0 |
| Feb 20, 2026 | Woods Keith | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Baffi Robert | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 17K | — | $0 |
| Feb 20, 2026 | Palekar Rohan | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Jordan Julie | Chief Medical Officer | Grant(A) | 30K | — | $0 |
| Feb 20, 2026 | Cvijic Christine Mikail | President and CFO | Grant(A) | 132K | — | $0 |
| Jun 12, 2025 | Noonberg Sarah B. | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Baffi Robert | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Woods Robert Keith | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Palekar Rohan | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Freedland Cory S. | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Woods Keith | Director | Grant(A) | 12K | — | $0 |
| May 14, 2025 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 7K | $15.15 | $103K |
| Mar 26, 2025 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 144K | — | $0 |
| Mar 26, 2025 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 24K | — | $0 |
| Mar 26, 2025 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 7K | — | $0 |
| Mar 26, 2025 | Jordan Julie | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Mar 26, 2025 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 43K | — | $0 |
| Mar 26, 2025 | Jordan Julie | Chief Medical Officer | Grant(A) | 8K | — | $0 |
| Mar 26, 2025 | Cvijic Christine Mikail | President and CFO | Grant(A) | 122K | — | $0 |
| Mar 26, 2025 | Cvijic Christine Mikail | President and CFO | Grant(A) | 20K | — | $0 |
| Mar 13, 2025 | Cvijic Christine Mikail | President and CFO | Sell(S) | 5K | $16.94 | $76K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 2K | $27.50 | $55K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 21K | $24.91 | $517K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 11K | $26.01 | $281K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 15K | $26.73 | $407K |
| Nov 22, 2024 | Cvijic Christine Mikail | President and CFO | Buy(P) | 24K | $20.48 | $492K |
| Nov 22, 2024 | McMinn Rachel | Chief Executive Officer, Director | Buy(P) | 48K | $20.40 | $969K |
| Jun 14, 2024 | Noonberg Sarah B. | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Baffi Robert | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Woods Robert Keith | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Palekar Rohan | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Freedland Cory S. | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Woods Keith | Director | Grant(A) | 8K | — | $0 |
| Mar 13, 2024 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 93K | — | $0 |
| Mar 13, 2024 | Cvijic Christine Mikail | President and CFO | Grant(A) | 32K | — | $0 |
| Mar 13, 2024 | Cvijic Christine Mikail | President and CFO | Grant(A) | 54K | — | $0 |
| Mar 13, 2024 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 34K | — | $0 |
| Mar 13, 2024 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 20K | — | $0 |
| Jan 16, 2024 | Palekar Rohan | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Woods Robert Keith | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Jordan Julie | Chief Medical Officer | Grant(A) | 75K | — | $0 |
| Jan 16, 2024 | Noonberg Sarah B. | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Freedland Cory S. | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Baffi Robert | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Woods Keith | Director | Grant(A) | 15K | — | $0 |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 310K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 93K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 222K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 21K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 1.2M | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 29K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 78K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 973K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 57K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 536K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 57K | — | $0 |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 536K | — | $0 |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 5K | $0.69 | $3K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 8K | $0.69 | $5K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 93K | $0.69 | $64K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 61K | $0.69 | $42K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 366 | $0.68 | $249 |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 208K | $0.68 | $141K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 17K | $0.68 | $12K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 4K | $0.68 | $3K |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 144K | $0.63 | $90K |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 358 | $0.67 | $240 |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 1.7M | $0.63 | $1.1M |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 4K | $0.67 | $3K |
| Aug 11, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Sell(S) | 1K | $0.62 | $820 |
| Aug 10, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Option exercise(M) | 5K | — | $0 |
| Aug 10, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Option exercise(M) | 5K | — | $0 |
| Jun 8, 2023 | Baker Brothers Life Sciences LP | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Baker Brothers Life Sciences LP | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Simpson Todd E | Director | Grant(A) | 25K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Neurogene Inc., SEC CIK 0001404644. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under NGNE and shows every filing by that issuer (also filed as NLTX, AQXP).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-11. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for NGNE